Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 1617Carcinoma, Renal Cell 497Urinary Bladder Neoplasms 459Carcinoma, Transitional Cell 233Breast Neoplasms 225Kidney Neoplasms 214Neoplasms 190Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 168Ovarian Neoplasms 161Melanoma 161Neoplasm Metastasis 142Lung Neoplasms 127Non-Muscle Invasive Bladder Neoplasms 104Pancreatic Neoplasms 101Stomach Neoplasms 99Uterine Cervical Neoplasms 91Squamous Cell Carcinoma of Head and Neck 86Endometrial Neoplasms 82Carcinoma, Hepatocellular 76Sarcoma 75Esophageal Neoplasms 71Head and Neck Neoplasms 68Adenocarcinoma 67Triple Negative Breast Neoplasms 65Colonic Neoplasms 53Testicular Neoplasms 52Disease 47Wilms Tumor 46Urologic Neoplasms 45

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian × Genitourinary × 1 year × Clear all
NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

AstraZeneca

Phase 2 Completed
298 enrolled 18 charts
BreastGastrointestinalGenitourinaryGynecologic

Ovarian

Data powered by HemOnc (CC BY 4.0) Colophon âš¡